Cambridge Research Biochemicals (Billingham, UK), the specialist peptide and custom antibody manufacturer, has announced a new partnership with the Molecular Probes business of Invitrogen Corporation, a provider of essential life science technologies for disease research and drug discovery (Carlsbad, CA, USA). The agreement grants Cambridge Research Biochemicals (CRB) a non-exclusive license to the full range of Molecular Probes dyes, including Alexa Fluor®, BODIPY®, Oregon Green® and Texas Red®fluorophores, enabling CRB to offer one of the most comprehensive custom labelling services available for fluorescent peptides. The license specifically allows CRB to attach all the proprietary dyes such as Alexa Fluor® dyes to its own custom-made peptides to meet customer requirements.
CRB has extensive experience of working with modern, smaller dyes and can help design peptides and strategies for labelling with dyes via a range of different chemistries. Its unique online dye selector provides a list of alternative dyes at similar wavelengths to enable the most appropriate choice of dye for labelling peptides and proteins for research purposes. The selector provides a simple process to choose the optimum dye based on specific applications and the attributes of each dye.
The Molecular Probes Alexa Fluor® dyes provide a number of benefits including: more intense fluorescence than other spectrally similar conjugates; better photostability, allowing more time for image capture; availability of conjugates in an array of distinct fluorescent colours from blue to infrared; and pH insensitivity that enables the dyes to remain highly fluorescent over a broad pH range; and high water solubility.
Emily Humphrys, CRB’s Commercial Director, said, “We are able to support a wide variety of discovery technologies such as FRET, Fluorescence Polarisation and multiplex assays. CRB is continuing to expand its range as we are actively seeking new fluorescent dyes and new dye applications for fluorescent labelled peptides, to provide the widest and most flexible choices for life science research and development.”